Aptimmune
Developer of an inactivated mucosal vaccine platform focused on preventing economically important swine viral diseases. Core activities include R&D of intranasal/mucosal vaccine formulations, development and use of a porcine macrophage-derived cell line for virus isolation and vaccine production, and commercialization partnerships to scale manufacturing and distribution.
Industries
Nr. of Employees
small (1-50)
Aptimmune
1234 Hanley Industrial Court, St. Louis, MO 63134
Products
Mucosal vaccine candidates for PRRSV and Influenza A in swine
Inactivated mucosal (intranasal) vaccine candidates aimed at preventing major swine respiratory viral pathogens.
Vaccine candidates under development for African Swine Fever (ASFV)
R&D programs focused on creating vaccines for ASFV for regions affected by the disease.
Porcine macrophage-derived cell line for virus research and diagnostics
A pig-derived macrophage cell line optimized for isolation and growth of swine viruses for diagnostic use and to support vaccine production.
Mucosal vaccine candidates for PRRSV and Influenza A in swine
Inactivated mucosal (intranasal) vaccine candidates aimed at preventing major swine respiratory viral pathogens.
Vaccine candidates under development for African Swine Fever (ASFV)
R&D programs focused on creating vaccines for ASFV for regions affected by the disease.
Porcine macrophage-derived cell line for virus research and diagnostics
A pig-derived macrophage cell line optimized for isolation and growth of swine viruses for diagnostic use and to support vaccine production.
Services
Partnerships with universities, diagnostic labs, CROs and CMOs to support virus isolation, R&D, and scale-up activities.
Access to regulatory expertise for animal vaccine registration and compliance through advisory partnerships.
Provision or licensing of specialized cell-line resources and related protocols to diagnostic providers to enhance PRRSV isolation and diagnostics.
Partnerships with universities, diagnostic labs, CROs and CMOs to support virus isolation, R&D, and scale-up activities.
Access to regulatory expertise for animal vaccine registration and compliance through advisory partnerships.
Provision or licensing of specialized cell-line resources and related protocols to diagnostic providers to enhance PRRSV isolation and diagnostics.
Expertise Areas
- Mucosal and intranasal vaccine development
- Swine viral vaccine R&D (PRRSV, IAV-S, ASFV)
- Cell line development for viral culture
- Viral diagnostics and isolation
Key Technologies
- Inactivated mucosal (intranasal) vaccine delivery
- Porcine macrophage-derived cell line for virus culture
- Cell culture scale-up for virus production
- Virus isolation techniques
News & Updates
Completed Series B financing raising more than $6 million; relocation of headquarters and laboratory to BRDG Park in St. Louis, MO to support commercialization and platform expansion.
Equity investment and global partnership granting exclusive rights outside the U.S. to manufacture and market the company's mucosal vaccine technology through a jointly managed business unit.
Selected by an agriculture technology accelerator for a nine-month program, receiving funding, mentorship and networking to support commercialization.
Recognized as Top Company at an investor-facing biotech innovation showcase and forum.
Article referencing a new cell line that may improve vaccine development and reliability for swine viruses.
Article discussing vaccine development efforts aimed at African Swine Fever.
Completed Series B financing raising more than $6 million; relocation of headquarters and laboratory to BRDG Park in St. Louis, MO to support commercialization and platform expansion.
Equity investment and global partnership granting exclusive rights outside the U.S. to manufacture and market the company's mucosal vaccine technology through a jointly managed business unit.
Selected by an agriculture technology accelerator for a nine-month program, receiving funding, mentorship and networking to support commercialization.
Recognized as Top Company at an investor-facing biotech innovation showcase and forum.
Article referencing a new cell line that may improve vaccine development and reliability for swine viruses.
Article discussing vaccine development efforts aimed at African Swine Fever.